The FDA's gene therapy regulator overseeing the review of cell and gene therapies is stepping down, according to an internal email obtained by STAT, marking a leadership change at an office that has become central to some of the most closely watched drug approvals in biotech. Vijay Kumar is leaving his post as acting director of the office, a shift that lands amid a busy stretch of biotech news.
What's Happening at the FDA
Kumar's departure removes a key decision-maker from the FDA division responsible for evaluating cell and gene therapies, a category of treatment that has grown rapidly in recent years as companies bring forward one-time genetic fixes for rare diseases and cancers. Leadership turnover in this office tends to draw close attention from biotech companies, since acting directors can shape how quickly and how strictly new gene therapy applications move through review.
STAT reported the change based on an email it obtained, though the agency has not detailed who will take over the role or what prompted the departure. Regulatory transitions like this one are often watched closely by drug developers with pending gene therapy applications, since a new reviewer can bring different priorities to ongoing evaluations.
Abivax Data Eases Safety Concerns
Elsewhere in biotech, Abivax disclosed additional data for its experimental ulcerative colitis drug, obefazimod, in a release that appears to have allayed at least some of the safety concerns that had flared around the treatment in recent weeks. Ulcerative colitis is a chronic inflammatory bowel disease, and obefazimod has been positioned as a potential oral alternative to some of the injectable biologics currently used to manage it.
Safety questions around experimental drugs can quickly move markets and shift investor sentiment, so the additional disclosure matters beyond the clinical details themselves — it signals how a single dataset can reset the narrative around a closely tracked drug candidate.
Other Biotech Moves to Watch
The same morning roundup also flagged continued investor interest in a biotech startup backed by Bain Capital, part of a broader pattern of private equity and venture money continuing to flow into biotech despite a choppier funding environment overall. Full details on the size and terms of that interest were reported separately in STAT's subscriber coverage.
Separately, the roundup referenced a Trump administration plan aimed at lowering prices for GLP-1 drugs, the class of weight-loss and diabetes medications that includes semaglutide and tirzepatide. GLP-1 pricing has become one of the most closely watched policy fights in health care, given how widely the drugs are now prescribed and how much they cost patients and insurers. For ongoing coverage of drug pricing policy and biotech investment trends, visit our business coverage and health coverage.
Why This Cluster of Biotech News Matters
Individually, a regulator's departure, one company's safety data, and a private funding round might seem like routine industry churn. Together, they illustrate how biotech's fortunes hinge on a mix of regulatory stability, clinical data, and investor confidence, and how quickly sentiment can shift when any one of those pieces moves. Companies awaiting gene therapy approvals, patients following ulcerative colitis treatment options, and investors tracking where private capital is flowing all have reason to watch how these threads develop in the coming weeks. Analysts note that FDA leadership changes in specialized review offices historically coincide with shifts in how aggressively new applications are scrutinized, adding another layer of uncertainty for companies with therapies awaiting sign-off.
